{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:46:33Z","timestamp":1790999193172,"version":"4.1.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Hereditary cystatin C amyloid angiopathy (HCCAA) is a lethal, dominantly inherited disease primarily affecting Icelandic young adults that leads to severe cerebral amyloid angiopathy, with no effective therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate safety, tolerance, and therapeutic potential of <jats:italic>N<\/jats:italic>-acetylcysteine (NAC) in lowering disease-associated biomarkers in sequence variation carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This phase 2a open-label clinical trial was conducted from March 2019 to December 2021 at a single study center at Landspitali University Hospital in Reykjavik, Iceland, and included 17 confirmed carriers of the L68Q-<jats:italic>CST3 <\/jats:italic>sequence variation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>High-dose NAC treatment was administered at 2400 mg daily for 9 months. Participants underwent regular monitoring for hemorrhages and disease progression, including blood and skin biopsy samples obtained every 3 months for biomarker testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcomes were drug tolerability and safety, cognitive status, and reduction in disease-associated biomarkers in skin biopsies. Secondary outcomes included changes in blood and plasma biomarker levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 17 carriers treated, 6 were male and 11 were female, and mean (SD) participant age was 40.0 (4.2) years. Analysis of the primary outcomes showed that NAC was safe and well tolerated. Five cerebral bleeds occurred during the treatment period without permanent neurological sequela; no death occurred. There was significant reduction in median (IQR) disease-specific biomarker levels in skin after treatment, including collagen IV (baseline: 3.69% [2.48%-5.16%]; after treatment: 2.60% [1.99%-2.97%]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), fibronectin (baseline: 3.17% [2.09%-5.05%]; after treatment: 2.37% [1.87%-3.42%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.01), vimentin (baseline: 1.60% [1.24%-2.37%]; after treatment: 1.31% [0.97%-1.68%]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), and SMAD (baseline: 2.25% [0.55%-4.36%]; after treatment: 1.56% [0.20%-2.54%]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) via Wilcoxon matched-pairs signed rank test. Secondary outcomes included a significant increase in reduced glutathione levels and decreased high-molecular-weight cystatin C aggregate levels in plasma after NAC treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this single-center nonrandomized clinical trial, NAC was safe and well tolerated and decreased disease-associated biomarker and amyloid deposition, suggesting NAC may offer a preventive strategy against HCCAA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrialsRegister.eu Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004776-56\/results\">2017-004776-56<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.0326","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:56:29Z","timestamp":1743436589000},"page":"486","source":"Crossref","is-referenced-by-count":6,"title":["<i>N<\/i>-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy"],"prefix":"10.1001","volume":"82","author":[{"given":"Asbjorg Osk","family":"Snorradottir","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"},{"name":"Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Gutierrez-Uzquiza","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pharmacy Faculty, Complutense University of Madrid, Madrid, Spain"},{"name":"Health Research Institute of the Cl\u00ednico San Carlos Hospital (IdISSC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Bragado","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pharmacy Faculty, Complutense University of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"March","sequence":"additional","affiliation":[{"name":"Center for Applied Genomics, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlly","family":"Kao","sequence":"additional","affiliation":[{"name":"Center for Applied Genomics, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Bernardo","family":"Arkink","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"},{"name":"Department of Radiology, Landsp\u00edtali University Hospital, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig","family":"Jonsdottir","sequence":"additional","affiliation":[{"name":"Arctic Therapeutics, Akureyri, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arna","family":"Sigurdardottir","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi J.","family":"Isaksson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekla Liv","family":"Mariasd\u00f3ttir","sequence":"additional","affiliation":[{"name":"Arctic Therapeutics, Akureyri, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Yr","family":"Bjorgvinsdottir","sequence":"additional","affiliation":[{"name":"Arctic Therapeutics, Akureyri, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia M.","family":"Kowal","sequence":"additional","affiliation":[{"name":"Arctic Therapeutics, Akureyri, Iceland"},{"name":"Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugrun L.","family":"Heimisdottir","sequence":"additional","affiliation":[{"name":"Arctic Therapeutics, Akureyri, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astros","family":"Sverrisdottir","sequence":"additional","affiliation":[{"name":"Department of Neurology, Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astridur","family":"Palsdottir","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Tomas","family":"Bjornsson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"},{"name":"Department of Genetics and Molecular Medicine, Landspitali University Hospital, Reykjavik, Iceland"},{"name":"Department of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Hakonarson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"},{"name":"Center for Applied Genomics, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Divisions of Human Genetics and Pulmonary Medicine, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"noi250009r1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-008-0366-2","article-title":"Cerebral amyloid angiopathy and its relationship to Alzheimer\u2019s disease.","volume":"115","author":"Thal","year":"2008","journal-title":"Acta Neuropathol"},{"issue":"1","key":"noi250009r2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"noi250009r3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-385883-2.00006-0","article-title":"Cerebral amyloid angiopathy.","volume":"107","author":"Yamada","year":"2012","journal-title":"Prog Mol Biol Transl Sci"},{"key":"noi250009r4","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13291","article-title":"The historical background of hereditary cystatin C amyloid angiopathy: genealogical, pathological, and clinical manifestations.","volume":"e13291","author":"Snorradottir","year":"2024","journal-title":"Brain Pathol"},{"issue":"8611","key":"noi250009r5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0140-6736(88)90641-1","article-title":"Mutation in cystatin C gene causes hereditary brain haemorrhage.","volume":"2","author":"Palsdottir","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"noi250009r6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/brain\/95.2.387","article-title":"Hereditary cerebral haemorrhage with amyloidosis.","volume":"95","author":"Gudmundsson","year":"1972","journal-title":"Brain"},{"issue":"1","key":"noi250009r7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1750-3639.2006.tb00561.x","article-title":"Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects.","volume":"16","author":"Palsdottir","year":"2006","journal-title":"Brain Pathol"},{"key":"noi250009r8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.brainres.2015.06.019","article-title":"Parenchymal cystatin C focal deposits and glial scar formation around brain arteries in hereditary cystatin C amyloid angiopathy.","volume":"1622","author":"Osk Snorradottir","year":"2015","journal-title":"Brain Res"},{"key":"noi250009r9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.brainres.2013.08.029","article-title":"Deposition of collagen IV and aggrecan in leptomeningeal arteries of hereditary brain haemorrhage with amyloidosis.","volume":"1535","author":"Snorradottir","year":"2013","journal-title":"Brain Res"},{"issue":"6","key":"noi250009r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000099","article-title":"A drastic reduction in the life span of cystatin C L68Q carriers due to life-style changes during the last two centuries.","volume":"4","author":"Palsdottir","year":"2008","journal-title":"PLoS Genet"},{"issue":"2","key":"noi250009r11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.STR.18.2.431","article-title":"Immunohistochemical characterization of the amyloid deposits and quantitation of pertinent cerebrospinal fluid proteins in hereditary cerebral hemorrhage with amyloidosis.","volume":"18","author":"L\u00f6fberg","year":"1987","journal-title":"Stroke"},{"key":"noi250009r12","first-page":"157","article-title":"Dementia in hereditary cystatin C amyloidosis.","volume":"317","author":"Bl\u00f6ndal","year":"1989","journal-title":"Prog Clin Biol Res"},{"issue":"4","key":"noi250009r13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF01605784","article-title":"Skin deposits in hereditary cystatin C amyloidosis.","volume":"417","author":"Benedikz","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"4","key":"noi250009r14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/labinvest.2016.133","article-title":"Pathological changes in basement membranes and dermal connective tissue of skin from patients with hereditary cystatin C amyloid angiopathy.","volume":"97","author":"Snorradottir","year":"2017","journal-title":"Lab Invest"},{"issue":"4","key":"noi250009r15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/BF00194306","article-title":"Hereditary cystatin C amyloid angiopathy: identification of the disease-causing mutation and specific diagnosis by polymerase chain reaction based analysis.","volume":"89","author":"Abrahamson","year":"1992","journal-title":"Hum Genet"},{"issue":"4","key":"noi250009r16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1073\/pnas.91.4.1416","article-title":"Increased body temperature accelerates aggregation of the Leu-68?Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy.","volume":"91","author":"Abrahamson","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"noi250009r17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1515\/BC.2002.032","article-title":"Physico-chemical properties of the N-terminally truncated L68Q cystatin C found in amyloid deposits of brain haemorrhage patients.","volume":"383","author":"Gerhartz","year":"2002","journal-title":"Biol Chem"},{"issue":"1","key":"noi250009r18","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/s41467-021-22120-4","article-title":"NAC blocks Cystatin C amyloid complex aggregation in a cell system and in skin of HCCAA patients.","volume":"12","author":"March","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"noi250009r21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(23)00114-X","article-title":"Progression of cerebral amyloid angiopathy: a pathophysiological framework.","volume":"22","author":"Koemans","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"noi250009r22","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/brain\/awx047","article-title":"Emerging concepts in sporadic cerebral amyloid angiopathy.","volume":"140","author":"Charidimou","year":"2017","journal-title":"Brain"},{"issue":"1","key":"noi250009r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","article-title":"Recent update on the heterogeneity of the Alzheimer\u2019s disease spectrum.","volume":"129","author":"Jellinger","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"issue":"1-2","key":"noi250009r24","first-page":"6","article-title":"Arfgengar heilableadingar a Islandi.","volume":"42","author":"Gudmundsson","year":"1989","journal-title":"L\u00e6knaneminn"},{"key":"noi250009r25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exer.2015.07.009","article-title":"Myofibroblasts.","volume":"142","author":"Hinz","year":"2016","journal-title":"Exp Eye Res"},{"issue":"1","key":"noi250009r26","doi-asserted-by":"publisher","first-page":"17300","DOI":"10.1038\/s41598-020-74179-6","article-title":"Dermal fibroblasts have different extracellular matrix profiles induced by TGF-\u00df, PDGF and IL-6 in a model for skin fibrosis.","volume":"10","author":"Juhl","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"noi250009r27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10020-019-0096-z","article-title":"Curcumin induced oxidative stress attenuation by N-acetylcysteine co-treatment: a fibroblast and epithelial cell in-vitro study in idiopathic pulmonary fibrosis.","volume":"25","author":"Rodriguez","year":"2019","journal-title":"Mol Med"},{"issue":"1","key":"noi250009r28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2009.09.026","article-title":"Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis.","volume":"48","author":"Liu","year":"2010","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"noi250009r29","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.ajpath.2017.07.018","article-title":"Reduced glutathione level promotes epithelial-mesenchymal transition in lens epithelial cells via a Wnt\/\u00df-catenin-mediated pathway: relevance for cataract therapy.","volume":"187","author":"Wei","year":"2017","journal-title":"Am J Pathol"},{"issue":"1","key":"noi250009r30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/gerona\/glac135","article-title":"Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial.","volume":"78","author":"Kumar","year":"2023","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"noi250009r31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1183\/09031936.04.00016804","article-title":"Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease.","volume":"23","author":"Dekhuijzen","year":"2004","journal-title":"Eur Respir J"},{"issue":"4","key":"noi250009r32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1515\/almed-2022-0111","article-title":"The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies.","volume":"3","author":"Sienes Bailo","year":"2022","journal-title":"Adv Lab Med"},{"issue":"2","key":"noi250009r33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/brb3.208","article-title":"N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.","volume":"4","author":"Bavarsad Shahripour","year":"2014","journal-title":"Brain Behav"},{"key":"noi250009r19","volume-title":"Dementia Rating Scale-2: DRS-2: Professional Manual","author":"Jurica","year":"2001"},{"key":"noi250009r20","volume-title":"Dementia Rating Scale","author":"Mattis","year":"1988"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2831917\/jamaneurology_snorradottir_2025_oi_250009_1746814073.87495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:01:47Z","timestamp":1747062107000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2831917"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.0326","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}